KTTA: חוב לטווח קצר של החברה Pasithea Therapeutics

Pasithea Therapeutics (KTTA) develops small molecules to combat severe psychiatric and brain disorders, diversifying risks across various CNS targeting methods. The business model relies on the search for neurofibromatosis treatments and the launch of ketamine therapy centers. The asset's price trajectory reflects the current stage of liquidity burn for clinical trials, with the indicator standing at 0.00.

This indicator measures the aggregate of liabilities with a maturity of up to one year, reflecting the issuer's ability to promptly service debt without incurring critical interest expenses. By analyzing the current volume of short-term liabilities, an investor can assess the financial flexibility of Pasithea Therapeutics (KTTA), which is critical for maintaining the academic environment and retaining rare neuroscience specialists through a stock option system.